Max Rosett
Directeur Financier/CFO chez IMMUNOME, INC.
Fortune : 283 147 $ au 30/04/2024
Profil
Max Rosett is currently working as the CFO, Chief Accounting Officer & EVP-Operations at Immunome, Inc. He previously worked as the Chief Operating Officer at MorphImmune, Inc. from 2022 to 2023 and as a Principal at Research Bridge Partners from 2018 to 2023.
Mr. Rosett graduated from the Georgia Institute of Technology in 2016 with a graduate degree and from Yale University in 2012 with an undergraduate degree.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMUNOME, INC.
0,03% | 16/05/2024 | 19 856 ( 0,03% ) | 283 147 $ | 30/04/2024 |
Postes actifs de Max Rosett
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNOME, INC. | Directeur Financier/CFO | 02/01/2024 |
Anciens postes connus de Max Rosett
| Sociétés | Poste | Fin |
|---|---|---|
Research Bridge Partners /Venture Capital/
 Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Corporate Officer/Principal | 01/11/2023 |
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Directeur des opérations | 01/10/2023 |
Formation de Max Rosett
| Yale University | Undergraduate Degree |
| Georgia Institute of Technology | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IMMUNOME, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
Research Bridge Partners /Venture Capital/
Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Finance |